Scilex Holding Co (SCLXW) Stock Price & Analysis
Scilex Holding Co (SCLXW) rose 0.00% to USD 0.14 as of June 10, 2026 at 13:40 UTC, according to Nexqual real-time market data.
SCLXW last closed at USD 0.14; the session ranged USD 0.14–0.14 on volume of 5 shares. Market capitalization is —, with a 52-week range of USD 0.14–0.14 (NCM). Source: Nexqual, June 10, 2026 at 13:40 UTC.
Key Statistics (as of June 10, 2026 at 13:40 UTC)
| Price | USD 0.14 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.14 |
| Open | USD 0.17 |
| Day Range | USD 0.14 – 0.14 |
| 52-Week Range | USD 0.14 – 0.14 |
| Volume | 5 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (SCLXW)
Nexqual's technical model rates SCLXW "BUY" based on 5 bullish and 1 bearish signals across 66 daily candles, as of June 10, 2026 at 13:40 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0.14) |
| MACD | 0 (negative) |
Analyst Ratings (SCLXW)
Wall Street analysts rate SCLXW "None", per Nexqual as of June 10, 2026 at 13:40 UTC.
| Consensus Rating | None |
|---|
Earnings (SCLXW)
Source: Nexqual, June 10, 2026 at 13:40 UTC.
Financials & Fundamentals (SCLXW)
| Total Revenue | $33.86M |
|---|---|
| Revenue Growth (YoY) | +72.10% |
| Gross Margin | +59.65% |
| Operating Margin | -373.49% |
| Profit Margin | +0.00% |
| Current Ratio | 0.08 |
| Total Cash | $3.36M |
| Total Debt | $106.36M |
| Free Cash Flow | $5.99M |
Source: Nexqual, June 10, 2026 at 13:40 UTC.
Financial Health Score (SCLXW)
Nexqual rates Scilex Holding Co's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 13:40 UTC.
| Growth | Critical — Revenue -47% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $3M cash vs $106M debt |
| Cash Flow | Strong — FCF $6M, 20% margin |
| Efficiency | Mixed — No data |
Ownership (SCLXW)
| Float | 5.19M |
|---|
Source: Nexqual, June 10, 2026 at 13:40 UTC.
Leadership (SCLXW)
Scilex Holding Co is led by Henry H. Ji (age 61), CEO, President & Executive Chairman, per Nexqual as of June 10, 2026 at 13:40 UTC.
| CEO, President & Executive Chairman | Henry H. Ji (age 61) |
|---|---|
| Senior VP, CFO, COO, Corporate Secretary & Director | Stephen Ma (age 52) |
Major Backers & Investors (SCLXW)
Notable institutional backers of Scilex Holding Co include Cruiser Capital Advisors, Llc, Landscape Capital Management LLC, Virtu Financial LLC, according to Nexqual as of June 10, 2026 at 13:40 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Cruiser Capital Advisors, Llc | 0.36% |
| Landscape Capital Management LLC | 0.31% |
| Virtu Financial LLC | 0.28% |
| RiverNorth Opportunities Fd | 0.26% |
Source: Nexqual, June 10, 2026 at 13:40 UTC.
From Scilex Holding Co's Latest SEC 10-K Filing (filed 2026-04-10)
Key Strengths & Strategy (as disclosed to the SEC)
- For example, poor adhesion of the patch is a leading problem for topical lidocaine patches cited in the FDA Adverse Event Reporting System ("FAERS").
Partnerships
- We acquired certain rights to GLOPERBA and the exclusive license to use the trademark "GLOPERBA®", pursuant to a License and Commercialization Agreement we entered into with RxOmeg Therapeutics LLC (a/k/a Romeg Therapeutics, LLC) ("Romeg"), dated as of June 14, 2022, which agreement was subsequently amended on January 16, 2025 (such agreement, as so amended, the "Romeg License Agreement").
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SCLX | Scilex Holding Company | USD 6.95 | ▲ 0.58% |
| CELU | Celularity Inc. | USD 0.73 | ▼ 10.1% |
| CELUW | Celularity Inc. | USD 0 | ▼ 51.72% |
| SMNR | Semnur Pharmaceuticals Inc. | USD 3.1 | ▼ 38% |
| AARD | Aardvark Therapeutics, Inc. | USD 3.52 | ▼ 1.95% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 13:40 UTC. This page is informational and not investment advice.